MARKET

XNCR

XNCR

Xencor
NASDAQ
11.22
-0.66
-5.56%
After Hours: 11.18 -0.04 -0.36% 16:56 05/15 EDT
OPEN
11.66
PREV CLOSE
11.88
HIGH
11.66
LOW
10.97
VOLUME
895.18K
TURNOVER
--
52 WEEK HIGH
18.69
52 WEEK LOW
6.92
MARKET CAP
831.87M
P/E (TTM)
-4.8817
1D
5D
1M
3M
1Y
5Y
1D
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR)
TipRanks · 2d ago
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
TipRanks · 4d ago
Trump Trade: U.S. plans AI security order without required model tests
TipRanks · 5d ago
Xencor Price Target Raised to $14.00/Share From $13.00 by JP Morgan
Dow Jones · 5d ago
Xencor Is Maintained at Neutral by JP Morgan
Dow Jones · 5d ago
Trump approves plan to fire FDA head Marty Makary, CBS reports
TipRanks · 5d ago
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)
TipRanks · 5d ago
Xencor price target raised to $14 from $13 at JPMorgan
TipRanks · 5d ago
More
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Webull offers Xencor Inc stock information, including NASDAQ: XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.